HomeCompareNURO vs FCPT

NURO vs FCPT: Dividend Comparison 2026

NURO yields 43.67% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NURO wins by $233.5K in total portfolio value
10 years
NURO
NURO
● Live price
43.67%
Share price
$4.58
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$282.6K
Annual income
$51,335.69
Full NURO calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — NURO vs FCPT

📍 NURO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNUROFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NURO + FCPT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NURO pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NURO
Annual income on $10K today (after 15% tax)
$3,711.79/yr
After 10yr DRIP, annual income (after tax)
$43,635.34/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, NURO beats the other by $38,726.35/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NURO + FCPT for your $10,000?

NURO: 50%FCPT: 50%
100% FCPT50/50100% NURO
Portfolio after 10yr
$165.8K
Annual income
$28,555.48/yr
Blended yield
17.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

NURO
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
-14.9
Piotroski
1/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NURO buys
0
FCPT buys
0
No recent congressional trades found for NURO or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNUROFCPT
Forward yield43.67%6.05%
Annual dividend / share$2.00$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$282.6K$49.1K
Annual income after 10y$51,335.69$5,775.28
Total dividends collected$217.9K$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: NURO vs FCPT ($10,000, DRIP)

YearNURO PortfolioNURO Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$15,067$4,366.81$11,401$700.92+$3.7KNURO
2$22,270$6,148.97$13,064$864.84+$9.2KNURO
3$32,324$8,494.27$15,051$1,072.48+$17.3KNURO
4$46,108$11,522.15$17,442$1,337.22+$28.7KNURO
5$64,697$15,360.67$20,340$1,677.08+$44.4KNURO
6$89,369$20,143.18$23,880$2,116.57+$65.5KNURO
7$121,629$26,004.42$28,241$2,689.36+$93.4KNURO
8$163,219$33,076.14$33,660$3,442.07+$129.6KNURO
9$216,127$41,482.53$40,456$4,439.95+$175.7KNURO
10$282,592$51,335.69$49,063$5,775.28+$233.5KNURO

NURO vs FCPT: Complete Analysis 2026

NUROStock

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Full NURO Calculator →

FCPTREIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this NURO vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NURO vs SCHDNURO vs JEPINURO vs ONURO vs KONURO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.